Research programme: hepatitis C virus therapeutics - Ambrilia Biopharma

Drug Profile

Research programme: hepatitis C virus therapeutics - Ambrilia Biopharma

Latest Information Update: 10 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambrilia Biopharma
  • Class Peptides; Small molecules
  • Mechanism of Action Hepatitis C protease inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 09 Jul 2013 Discontinued for Hepatitis C in Canada prior to 9 July 2013 (unspecified route)
  • 10 Jan 2011 Early research in Hepatitis C in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top